Hydrea (Hydroxyurea): Cytoreductive Therapy for Myeloproliferative Neoplasms and Sickle Cell Disease - Evidence-Based Review

Product Description Hydrea, known generically as hydroxyurea, is not a dietary supplement or a common medical device. It is a potent, prescription-only antineoplastic and antimetabolite medication. Its primary use is in hematology and oncology for the management of specific myeloproliferative disorders and solid tumors. This monograph is structured to provide a comprehensive, evidence-based overview for healthcare professionals and highly informed patients, detailing its pharmacology, clinical applications, and critical safety profile. The information herein is derived from clinical guidelines, prescribing information, and peer-reviewed literature.